DBV received a complete response letter from the FDA in August 2020, citing adhesion and efficacy concerns with the patch.
The study is enrolling male participants aged between 12 and 50 years who have a confirmed XLRP diagnosis.
Targeted patient recruitment can increase the likelihood of trial success and help cultivate use of precision medicine.
The TRC found that the therapy demonstrated targeted tumour activity and a low uptake in kidneys and other vital organs.
Increasing clinical trial activity across the APAC region is impacting global commercial supply routes.
China’s influence in global pharma is rising, but as US tensions escalate, other nations are showing their potential.
